Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Just Reported Annual Earnings And Analysts Are Lifting Their Estimates [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Revenues of US$17m beat estimates by a substantial 80% margin. Unfortunately, Tarsus Pharmaceuticals also reported a statutory loss of US$4.62 per share, which at least was smaller than the analysts expected. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. See our latest analysis for Tarsus Pharmaceuticals Taking into account the latest results, the current consensus from Tarsus Pharmaceuticals' five analysts is for revenues of US$96.6m in 2024. This would reflect a substantial 454% increase on its revenue over the past 12 months. Losses are expected to increase substantially, hitting US$4.55 per share. Before this earnings announcement, the analysts had been modelling reve
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon [Yahoo! Finance]Yahoo! Finance
- Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from PharmakonGlobeNewswire
- Insider Returns Down To US$166k As Tarsus Pharmaceuticals' Stock Dips 14% [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why [Yahoo! Finance]Yahoo! Finance
- Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name [Seeking Alpha]Seeking Alpha
TARS
Earnings
- 2/27/24 - Beat
TARS
Sec Filings
- 4/26/24 - Form ARS
- 4/26/24 - Form DEFA14A
- 4/26/24 - Form DEF
- TARS's page on the SEC website